Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

918 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia.
Shigematsu A, Tanaka J, Suzuki R, Atsuta Y, Kawase T, Ito YM, Yamashita T, Fukuda T, Kumano K, Iwato K, Yoshiba F, Kanamori H, Kobayashi N, Fukuhara T, Morishima Y, Imamura M. Shigematsu A, et al. Among authors: morishima y. Int J Hematol. 2011 Nov;94(5):463-71. doi: 10.1007/s12185-011-0944-2. Epub 2011 Nov 1. Int J Hematol. 2011. PMID: 22042561 Free article.
Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study.
Morishima Y, Ogura M, Nishimura M, Yazaki F, Bessho M, Mizoguchi H, Chiba S, Hirai H, Tauchi T, Urabe A, Takahashi M, Ohnishi K, Yokozawa T, Emi N, Hirano M, Shimazaki C, Nakao S, Kawai Y, Fujimoto M, Taguchi H, Jinnai I, Ohno R. Morishima Y, et al. Int J Hematol. 2004 Oct;80(3):261-6. doi: 10.1532/ijh97.04074. Int J Hematol. 2004. PMID: 15540902 Clinical Trial.
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
Ogura M, Morishima Y, Kobayashi Y, Uike N, Sugai S, Chou T, Kasai M, Miura I, Murayama T, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K; Cladribine Study Group. Ogura M, et al. Among authors: morishima y. Int J Hematol. 2004 Oct;80(3):267-77. doi: 10.1532/ijh97.04077. Int J Hematol. 2004. PMID: 15540903 Clinical Trial.
CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases.
Kawase T, Hamazaki M, Ogura M, Kawase Y, Murayama T, Mori Y, Nagai H, Tateno M, Oyama T, Kamiya Y, Taji H, Kagami Y, Naoe T, Takahashi T, Morishima Y, Nakamura S. Kawase T, et al. Among authors: morishima y. Int J Hematol. 2005 May;81(4):323-9. doi: 10.1532/IJH97.04142. Int J Hematol. 2005. PMID: 15914364
Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor.
Kanda Y, Sakamaki H, Sao H, Okamoto S, Kodera Y, Tanosaki R, Kasai M, Hiraoka A, Takahashi S, Miyawaki S, Kawase T, Morishima Y, Kato S; Japan Marrow Donor Program. Kanda Y, et al. Among authors: morishima y. Biol Blood Marrow Transplant. 2005 Nov;11(11):881-9. doi: 10.1016/j.bbmt.2005.07.005. Biol Blood Marrow Transplant. 2005. PMID: 16275591 Free article.
918 results